Denosumab and bisphosphonates: Different mechanisms of action and effects

Bone

Volumn 48, Issue 4, 2011, Pages 677-692

  Baron, Roland ^a,b   Ferrari, Serge ^c   Russell, R Graham G ^d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Denosumab; Osteoclast; Osteoporosis; RANK ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; GERANYLTRANSFERASE; IBANDRONIC ACID; LASOFOXIFENE; ODANACATIB; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PLACEBO; PREDNISOLONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SIGNAL PEPTIDE; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELL ACTIVITY; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULITIS; CORTICAL BONE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMUR SUBTROCHANTERIC FRACTURE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HUMAN; INHIBITION KINETICS; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BINDING; PROTEIN PRENYLATION; REVIEW; SIGNAL TRANSDUCTION; TRABECULAR BONE; VERTEBRA FRACTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND;

EID: 79952698455     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.11.020     Document Type: Review

References (195)

1. Schaffler M.B. Role of bone turnover in microdamage. Osteoporos Int 2003, 14(Suppl 5):S73-S77. (discussion S77-80).
2. Martin T., Gooi J.H., Sims N.A. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 2009, 19:73-88.
3. Bruzzaniti A., Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 2006, 7:123-139.
4. Russell G., Mueller G., Shipman C., Croucher P. Clinical disorders of bone resorption. Novartis Found Symp 2001, 232:251-267. (discussion 267-71).
5. Khosla S., Riggs B.L., Robb R.A., Camp J.J., Achenbach S.J., Oberg A.L., et al. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocrinol Metab 2005, 90:5096-5103.
6. Seeman E. Invited review: pathogenesis of osteoporosis. J Appl Physiol 2003, 95:2142-2151.
7. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
8. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
9. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
10. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008, 83:64-76.
11. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., Pangrazio A., Susani L., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
12. Cundy T., Davidson J., Rutland M.D., Stewart C., DePaoli A.M. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005, 353:918-923.
13. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360.
14. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
15. Elford P.R., Felix R., Cecchini M., Trechsel U., Fleisch H. Murine osteoblastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture. Calcif Tissue Int 1987, 41:151-156.
16. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
17. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
18. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
19. Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol 2008, 181:4742-4751.
20. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009, 5:667-676.
21. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
22. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15:457-475.
23. Wright H.L., McCarthy H.S., Middleton J., Marshall M.J. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009, 2:56-64.
24. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.
25. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med 1993, 178:1733-1744.
26. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
27. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
28. Niida S., Kaku M., Amano H., Yoshida H., Kataoka H., Nishikawa S., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999, 190:293-298.
29. Niida S., Kondo T., Hiratsuka S., Hayashi S., Amizuka N., Noda T., et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci USA 2005, 102:14016-14021.
30. Stewart A.F., Vignery A., Silverglate A., Ravin N.D., LiVolsi V., Broadus A.E., et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982, 55:219-227.
31. Martin T.J., Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005, 11:76-81.
32. Pierroz D.D., Bonnet N., Baldock P.A., Ominsky M.S., Stolina M., Kostenuik P.J., et al. Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010, 285:28164-28173.
33. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 2008, 105:20764-20769.
34. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006, 4:111-121.
35. Sims N. EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts. IBMS BoneKEy 2010, 7:304-313.
36. Henriksen K., Neutzsky-Wulff A.V., Bonewald L.F., Karsdal M.A. Local communication on and within bone controls bone remodeling. Bone 2009, 44:1026-1033.
37. Recker R.R., Marin F., Ish-Shalom S., Moricke R., Hawkins F., Kapetanos G., et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24:1358-1368.
38. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
39. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
40. Hughes D.E., MacDonald B.R., Russell R.G.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989, 83:1930-1935.
41. Boonekamp P.M., van der Wee-Pals L.J., van Wijk-van Lennep M.M., Thesing C.W., Bijvoet O.L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986, 1:27-39.
42. Mabilleau G., Kwaasi A.A., Sabokbar A., Tsoumpra M., Ebetino F.H., Russell R.G.G. Bisphosphonates affect human osteoclast development in vitro. Bone 2010, 46:S63-S64. (Abstract 149).
43. Francis M.D., Russell R.G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969, 165:1264-1266.
44. Benedict J.J. The physical chemistry of the disphosphonates - its relationship to their medical activity. Symposium CEMO (Centre d'Etude des Maladies Ostéo-articulaires de Genève) IV: diphosphonates and bone, Nyon (Switzerland), November 1-4, 1981 1982, 1-19. Editions Médecine et Hygiène, Geneva. A. Donath, B. Courvoisier (Eds.).
45. Ebrahimpour A., Francis M.D. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. Bisphosphonate on bones 1995, 125-136. Elsevier, Amsterdam. O.L.M. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
46. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient 2000, Academic Press, New York. 4th ed.
47. Henneman Z.J., Nancollas G.H., Ebetino F.H., Russell R.G., Phipps R.J. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008, 85:993-1000.
48. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
49. Ebetino F.H., Francis M.D., Rogers M.J., Russell R.G.G. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother 1998, 9:233-243.
50. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
51. Thompson K., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69:1624-1632.
52. Coxon F.P., Taylor A. Vesicular trafficking in osteoclasts. Semin Cell Dev Biol 2008, 19:424-433.
53. van Beek E., Löwik C., Que I., Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 1996, 11:1492-1497.
54. Frith J.C., Mönkkönen J., Auriola S., Mönkkönen H., Rogers M.J. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001, 44:2201-2210.
55. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
56. Ominsky M.S., Kostenuik P.J., Cranmer P., Smith S.Y., Atkinson J.E. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007, 18:1073-1082.
57. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-892.
58. Schwarz E.M., Ritchlin C.T. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007, 9(Suppl 1):S7.
59. Sordillo E.M., Pearse R.N. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003, 97:802-812.
60. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
61. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-88.
62. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
63. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367.
64. Amgen Europe B.V. Prolia™ (denosumab) European Union summary of product characteristics Accessed Sep 7, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf.
65. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
66. Stolina M., Dwyer D., Middleton S., Adamu S., Ominsky M.S., Zack D., et al. OPG prevents osteopenia in arthritic rats via different mechanisms than bisphosphonate therapy. J Bone Miner Res 2007, 22(Suppl 1):S475. [abstract].
67. Tat S.K., Padrines M., Theoleyre S., Couillaud-Battaglia S., Heymann D., Redini F., et al. OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 2006, 39:706-715.
68. Lambert C., Oury C., Dejardin E., Chariot A., Piette J., Malaise M., et al. Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 2007, 22:1350-1361.
69. Samadfam R., Xia Q., Goltzman D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 2007, 22:55-63.
70. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
71. Gasser J.A., Ingold P., Venturiere A., Shen V., Green J.R. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008, 23:544-551.
72. Teti A., Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 2009, 44:11-16.
73. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 2008, 42:606-615.
74. Kamiya N., Ye L., Kobayashi T., Mochida Y., Yamauchi M., Kronenberg H.M., et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008, 135:3801-3811.
75. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30:3071-3085.
76. Ominsky M.S., Stolina M., Li X., Corbin T.J., Asuncion F.J., Barrero M., et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 2009, 24:1234-1246.
77. Li X., Ominsky M.S., Stolina M., Warmington K.S., Geng Z., Niu Q.T., et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 2009, 45:669-676.
78. Aguirre J.I., Plotkin L.I., Stewart S.A., Weinstein R.S., Parfitt A.M., Manolagas S.C., et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006, 21:605-615.
79. Bonewald L.F. Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci 2007, 1116:281-290.
80. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
81. Plotkin L.I., Manolagas S.C., Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006, 39:443-452.
82. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
83. Plotkin L.I., Goellner J., Vyas K., Shelton R.S., Wynne R.A., Weinstein R.S., et al. A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo. J Bone Miner Res 2007, 22(Suppl 1):S4. [abstract].
84. Kogianni G., Mann V., Ebetino F., Nuttall M., Nijweide P., Simpson H., et al. Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 2004, 75:2879-2895.
85. Follet H., Li J., Phipps R.J., Hui S., Condon K., Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007, 40:1172-1177.
86. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16:2950-2960.
87. Fuchs R.K., Shea M., Durski S.L., Winters-Stone K.M., Widrick J., Snow C.M. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 2007, 41:290-296.
88. Lespessailles E., Jaffre C., Beaupied H., Nanyan P., Dolleans E., Benhamou C.L., et al. Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?. Calcif Tissue Int 2009, 85:146-157.
89. Stadelmann V.A., Bonnet N., Pioletti D.P. Combined effects of zoledronate and mechanical stimulation on bone adaptation in axially loaded mouse tibia. Clin Biomech 2011, 26:101-105.
90. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
91. Bachmann M.F., Wong B.R., Josien R., Steinman R.M., Oxenius A., Choi Y. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999, 189:1025-1031.
92. Ashcroft A.J., Cruickshank S.M., Croucher P.I., Perry M.J., Rollinson S., Lippitt J.M., et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003, 19:849-861.
93. Hi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 2005, 54:78-86.
94. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
95. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427.
96. Schett G., Middleton S., Bolon B., Stolina M., Brown H., Zhu L., et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005, 52:1604-1611.
97. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-792.
98. Stolina M., Schett G., Dwyer D., Vonderfecht S., Middleton S., Duryea D., et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies. Arthritis Res Ther 2009, 11:R187.
99. Verdrengh M., Bokarewa M., Ohlsson C., Stolina M., Tarkowski A. RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis. Bone 2010, 46:752-758.
100. Ferrari-Lacraz S., Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporos Int 2010, 22:435-446.
101. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
102. Bock O., Boerst H., Thomasius F.E., Degner C., Stephan-Oelkers M., Valentine S.M., et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007, 7:144-148.
103. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54:1838-1846.
104. Strampel W., Emkey R., Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007, 30:755-763.
105. Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19:278-288.
106. Raikkonen J., Crockett J.C., Rogers M.J., Monkkonen H., Auriola S., Monkkonen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157:427-435.
107. Benzaid I., Clezardin P. Nitrogen-containing bisphosphonates and human γδ T cells. IBMS BoneKEy 2010, 7:208-217.
108. Srivastava T., Haney C.J., Alon U.S. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 2009, 24:334-337.
109. Hak A.E., Pols H.A., van Hemert A.M., Hofman A., Witteman J.C. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000, 20:1926-1931.
110. Szulc P., Kiel D.P., Delmas P.D. Calcifications in the abdominal aorta predict fractures in men: MINOS study. J Bone Miner Res 2008, 23:95-102.
111. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
112. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., Averill M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124.
113. Helas S., Goettsch C., Schoppet M., Zeitz U., Hempel U., Morawietz H., et al. Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009, 175:473-478.
114. Fleisch H.A., Russell R.G., Bisaz S., Muhlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970, 1:12-18.
115. Price P.A., Faus S.A., Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001, 21:817-824.
116. Price P.A., Omid N., Than T.N., Williamson M.K. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 2002, 71:356-363.
117. Monney P., Nguyen Q.V., Perroud H., Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004, 19:2130-2132.
118. Schliep S., Schuler G., Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol 2008, 18:554-556.
119. Santini D., Schiavon G., Angeletti S., Vincenzi B., Gasparro S., Grilli C., et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?. Recent Pat Anticancer Drug Discov 2006, 1:383-396.
120. Stresing V., Daubine F., Benzaid I., Monkkonen H., Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257:16-35.
121. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
122. Rodan G., Reszka A., Golub E., Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004, 20:1291-1300.
123. Reitsma P.H., Bijvoet O.L., Verlinden-Ooms H., van der Wee-Pals L.J. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 1980, 32:145-157.
124. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
125. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109-3115.
126. Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004, 15:792-798.
127. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
128. Ste-Marie L.G., Sod E., Johnson T., Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476.
129. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75-85.
130. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
131. Cremers S., Sparidans R., den H.J., Hamdy N., Vermeij P., Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002, 57:883-890.
132. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003, 18:852-858.
133. Ominsky M.S., Li X., Asuncion F.J., Barrero M., Warmington K.S., Dwyer D., et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008, 23:672-682.
134. Calvi L.M., Sims N.A., Hunzelman J.L., Knight M.C., Giovannetti A., Saxton J.M., et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001, 107:277-286.
135. Ohishi M., Chiusaroli R., Ominsky M., Asuncion F., Thomas C., Khatri R., et al. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am J Pathol 2009, 174:2160-2171.
136. Jämsä T., Rho J.Y., Fan Z., MacKay C.A., Marks S.C., Tuukkanen J. Mechanical properties in long bones of rat osteopetrotic mutations. J Biomech 2002, 35:161-165.
137. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
138. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003, 18:512-520.
139. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
140. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
141. Allen M.R., Burr D.B. Skeletal microdamage: less about biomechanics and more about remodeling. Clin Rev Bone Miner Metab 2008, 6:24-30.
142. Burr D.B., Allen M.R. Low bone turnover and microdamage? How and where to assess it?. J Bone Miner Res 2008, 23:1150-1151.
143. Chapurlat R.D., Delmas P.D. Bone microdamage: a clinical perspective. Osteoporos Int 2009, 20:1299-1308.
144. Dobnig H., Stepan J.J., Burr D.B., Li J., Michalska D., Sipos A., et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009, 24:1998-2006.
145. Johnston S., Andrews S., Shen V., Cosman F., Lindsay R., Dempster D.W., et al. The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology 2007, 148:4466-4474.
146. Pettway G.J., Meganck J.A., Koh A.J., Keller E.T., Goldstein S.A., McCauley L.K. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 2008, 42:806-818.
147. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
148. Hofbauer L.C., Zeitz U., Schoppet M., Skalicky M., Schuler C., Stolina M., et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009, 60:1427-1437.
149. Gerstenfeld L.C., Sacks D.J., Pelis M., Mason Z.D., Graves D.T., Barrero M., et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009, 24:196-208.
150. Ominsky M.S., Schroeder J., Smith S.Y., Farrell D.J., Atkinson J.E., Kostenuik P.J. Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys. J Bone Miner Res 2007, 22(Suppl 1). [abstract], [Abstract 1082].
151. Ominsky M., Smith S., Jolette J., Vlasseros F., Samadfam R., Kostenuik P. Decreased fluorochrome labeling in bone biopsies from denosumab-treated cynomolgus monkeys is related to reductions in cortical porosity and trabecular eroded surfaces. J Bone Miner Res 2009, 24(Suppl 1). [abstract], [Abstract A09001682].
152. Ominsky M.S., Jolette J., Smith S.Y., Vlasseros F., Samadfam R., Kostenuik P.J. Transition from alendronate to denosumab resulted in further reductions in local and systemic bone turnover parameters and reduced cortical porosity in ovariectomized cynomolgus monkeys. J Bone Miner Res 2008, 23(Suppl 1):S61. [abstract].
153. Chesnut I.C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
154. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
155. Fogelman I., Ribot C., Smith R., Ethgen D., Sod E., Reginster J.Y. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000, 85:1895-1900.
156. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
157. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
158. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
159. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
160. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
161. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
162. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
163. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229. AMG 162 Bone Loss Study Group.
164. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
165. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
166. Ferrari S. Bisphosphonates and denosumab: do they thicken bone cortices, and can these changes be assessed by high-resolution pQCT?. IBMS BoneKEy 2010, 7:182-186.
167. Borah B., Dufresne T., Nurre J., Phipps R., Chmielewski P., Wagner L., et al. Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res 2010, 25:41-47.
168. Pazianas M., Cooper C., Ebetino F.H., Russell R.G. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010, 6:325-343.
169. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117.
170. Almazrooa S.A., Woo S.B. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009, 140:864-875.
171. Taylor K.H., Middlefell L.S., Mizen K.D. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010, 48:221-223.
172. Aghaloo T.L., Felsenfeld A.L., Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010, 68:959-963.
173. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
174. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
175. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
176. Green J.R., Seltenmeyer Y., Jaeggi K.A., Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997, 80:225-230.
177. Perazella M.A., Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 2008, 74:1385-1393.
178. Genentech Inc. Boniva® (ibandronate sodium) tablets US prescribing information Accessed Sep 7, 2010. http://www.gene.com/gene/products/information/boniva/pdf/pi.pdf.
179. Genentech Inc Boniva® (ibandronate sodium) injection US prescribing information Accessed Sep 7, 2010. http://www.gene.com/gene/products/information/boniva/pdf/Injection_pi.pdf.
180. Merck and Co.Inc Fosamax® (alendronate sodium) US prescribing information Accessed Sep 7, 2010. http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf.
181. Novartis Pharmaceuticals Corporation Reclast® (zoledronic acid) US prescribing information Accessed Sep 7, 2010. http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf.
182. Warner Chilcott Pharmaceuticals Inc. Actonel® (risedronate sodium) US prescribing information Accessed Sep 7, 2010. http://www.actonel.com/global/prescribing_information.pdf.
183. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
184. Miller P.D., Roux C., Boonen S., Barton I.P., Dunlap L.E., Burgio D.E. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20:2105-2115.
185. Miller P.D., Miday R., Klemes A., Ramsey D. Renal safety across a wide range of dosing regimens of risedronate. J Bone Miner Res 2008, 23(Suppl 1):SA402.
186. Jamal S.A., Ljunggren O., Stehman-Breen C., Cummings S., McClung M., Goemaere S., et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function. Bone 2010, 47(Suppl 1):S207-S208. [abstract].
187. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
188. Ferrari S. Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture. Osteoporos Int 2010, 21(Suppl 2):S437-S442.
189. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
190. Recker R.R., Ste-Marie L.G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D., et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 2010, 46:660-665.
191. Ominsky M.S., Li X., Tan H., Asuncion F.J., Barrero M., Tian X.Y., et al. The effects of alendronate or denosumab on cortical and trabecular bone mass, bone strength, and bone mass-strength relationships in mice. J Bone Miner Res 2008, 23(Suppl 1):S40. [abstract].
192. Miller P.D. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009, 7:18-22.
193. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281-290.
194. McClung M.R. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 2006, 4:28-33.
195. Hiraga T., Tanaka S., Yamamoto M., Nakajima T., Ozawa H. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 1996, 18:1-7.